Skip to main content

Table 4 Carotid CMR total wall volume changes in the ITT population

From: Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance

 

Treatment Group

Week 52

Rosiglitazone

Placebo

(mm 3 )

(N = 25)

(N = 29)

Number with baseline and week 52 CMR scans

21

26

Baseline (mean ± SD)

1354 ± 532

1146 ± 550

End of treatment (mean ± SD)

1348 ± 531

1134 ± 523

Change from baseline

  

   mean ± SD

-5.7 ± 79.4

-12.1 ± 104.6

Model adjusted change from baseline1

  

   mean ± SE

12.7 ± 22.8

-2.9 ± 20.9

Difference from placebo1

  

   mean

15.7

-

   95% CI

-39.5, 70.9

-

   P-value

0.57

-

  1. 1. Adjusted for stratum + baseline value + treatment.